Is Infinium Pharma overvalued or undervalued?

As of 6 October 2025, the valuation grade for Infinium Pharma has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued based on its high valuation ratios, including a PE ratio of 45.35, an EV to EBITDA of 26.13, and a Price to Book Value of 3.63. These figures suggest that investors are paying a premium for the stock relative to its earnings and book value.
In comparison to its peers, Infinium Pharma's valuation stands out as particularly high. For instance, Sun Pharma has a PE ratio of 34.56 and an EV to EBITDA of 23.42, while Cipla offers a more attractive valuation with a PE of 22.72 and an EV to EBITDA of 15.97. This discrepancy highlights that Infinium Pharma is not only overvalued relative to its immediate competitors but also underperforms in terms of returns, with a year-to-date stock return of -17.81% compared to the Sensex's gain of 6.06%.